Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.

Rizk DV, Saha MK, Hall S, Novak L, Brown R, Huang ZQ, Fatima H, Julian BA, Novak J.

J Am Soc Nephrol. 2019 Oct;30(10):2017-2026. doi: 10.1681/ASN.2018111156. Epub 2019 Aug 23.

PMID:
31444275
2.

The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.

Rizk DV, Maillard N, Julian BA, Knoppova B, Green TJ, Novak J, Wyatt RJ.

Front Immunol. 2019 Mar 19;10:504. doi: 10.3389/fimmu.2019.00504. eCollection 2019. Review.

3.

Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.

Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, Cattran DC, Chishti AS, D'Agati VD, D'Alessandri-Silva CJ, Gbadegesin RA, Hogan JJ, Iragorri S, Jennette JC, Julian BA, Khalid M, Lafayette RA, Liapis H, Lugani F, Mansfield SA, Mason S, Nachman PH, Nast CC, Nester CM, Noone DG, Novak J, O'Shaughnessy MM, Reich HN, Rheault MN, Rizk DV, Saha MK, Sanghani NS, Sperati CJ, Sreedharan R, Srivastava T, Swiatecka-Urban A, Twombley K, Vasylyeva TL, Weaver DJ, Yin H, Zee J, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Flessner M, Guay-Woodford LM, Kiryluk K; CureGN Consortium.

Kidney Int Rep. 2018 Aug 3;3(6):1373-1384. doi: 10.1016/j.ekir.2018.07.021. eCollection 2018 Nov.

4.

Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy.

Novak J, Barratt J, Julian BA, Renfrow MB.

Semin Nephrol. 2018 Sep;38(5):461-476. doi: 10.1016/j.semnephrol.2018.05.016. Review.

PMID:
30177018
5.

Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients.

Reily C, Rizk DV, Julian BA, Novak J.

Biotechniques. 2018 Aug;65(2):71-77. doi: 10.2144/btn-2018-0042.

6.

Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.

Langefeld CD, Comeau ME, Ng MCY, Guan M, Dimitrov L, Mudgal P, Spainhour MH, Julian BA, Edberg JC, Croker JA, Divers J, Hicks PJ, Bowden DW, Chan GC, Ma L, Palmer ND, Kimberly RP, Freedman BI.

Kidney Int. 2018 Sep;94(3):599-607. doi: 10.1016/j.kint.2018.03.017. Epub 2018 Jun 7.

7.

Secondary IgA nephropathy.

Saha MK, Julian BA, Novak J, Rizk DV.

Kidney Int. 2018 Oct;94(4):674-681. doi: 10.1016/j.kint.2018.02.030. Epub 2018 May 24. Review.

PMID:
29804660
8.

Population Health, Ethnicity, and Rate of Living Donor Kidney Transplantation.

Reed RD, Sawinski D, Shelton BA, MacLennan PA, Hanaway M, Kumar V, Long D, Gaston RS, Kilgore ML, Julian BA, Lewis CE, Locke JE.

Transplantation. 2018 Dec;102(12):2080-2087. doi: 10.1097/TP.0000000000002286.

PMID:
29787519
9.

Redefining the Influence of Ethnicity on Simultaneous Kidney and Pancreas Transplantation Outcomes: A 15-Year Single-Center Experience.

Young CJ, MacLennan PA, Mannon EC, Reed RD, Shelton BA, Hanaway MJ, Agarwal G, Gaston RS, Julian BA, Kew CE 2nd, Kumar V, Mannon RB, Mehta S, Ong SC, Towns GC, Deierhoi MH, Locke JE.

Ann Surg. 2018 May 17. doi: 10.1097/SLA.0000000000002816. [Epub ahead of print]

PMID:
29781845
10.

Evaluation of Potential Living Kidney Donors in the APOL1 Era.

Freedman BI, Julian BA.

J Am Soc Nephrol. 2018 Apr;29(4):1079-1081. doi: 10.1681/ASN.2018020137. Epub 2018 Mar 9. No abstract available.

11.

Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy.

Hastings MC, Bursac Z, Julian BA, Villa Baca E, Featherston J, Woodford SY, Bailey L, Wyatt RJ.

Kidney Int Rep. 2017 Aug 24;3(1):99-104. doi: 10.1016/j.ekir.2017.08.008. eCollection 2018 Jan.

12.

Serial Galactose-Deficient IgA1 Levels in Children with IgA Nephropathy and Healthy Controls.

Sanders JT, Hastings MC, Moldoveanu Z, Novak J, Julian BA, Bursac Z, Wyatt RJ.

Int J Nephrol. 2017;2017:8210641. doi: 10.1155/2017/8210641. Epub 2017 Nov 26.

13.

Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy.

Placzek WJ, Yanagawa H, Makita Y, Renfrow MB, Julian BA, Rizk DV, Suzuki Y, Novak J, Suzuki H.

PLoS One. 2018 Jan 11;13(1):e0190967. doi: 10.1371/journal.pone.0190967. eCollection 2018.

14.

Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy.

Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H, Ueda H, Moldoveanu Z, Kiryluk K, Suzuki Y, Wyatt RJ, Tomino Y, Gharavi AG, Weinmann A, Julian BA, Willey CD, Novak J.

Kidney Int Rep. 2017 Jul 19;2(6):1194-1207. doi: 10.1016/j.ekir.2017.07.002. eCollection 2017 Nov.

15.

Apolipoprotein L1 Gene Effects on Kidney Transplantation.

Freedman BI, Locke JE, Reeves-Daniel AM, Julian BA.

Semin Nephrol. 2017 Nov;37(6):530-537. doi: 10.1016/j.semnephrol.2017.07.006. Review.

16.

Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

Yanik MV, Irvin MR, Beasley TM, Jacobson PA, Julian BA, Limdi NA.

Pharmacotherapy. 2017 Nov;37(11):1366-1373. doi: 10.1002/phar.2032. Epub 2017 Nov 2.

17.

Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation.

Berthoux F, Suzuki H, Mohey H, Maillard N, Mariat C, Novak J, Julian BA.

J Am Soc Nephrol. 2017 Jun;28(6):1943-1950. doi: 10.1681/ASN.2016060670. Epub 2017 Mar 2.

18.

GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway.

Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, Shapiro S, LeDesma RA, Bradbury D, Ionita-Laza I, Eitner F, Rauen T, Maillard N, Berthoux F, Floege J, Chen N, Zhang H, Scolari F, Wyatt RJ, Julian BA, Gharavi AG, Novak J.

PLoS Genet. 2017 Feb 10;13(2):e1006609. doi: 10.1371/journal.pgen.1006609. eCollection 2017 Feb.

19.

Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors.

Locke JE, Sawinski D, Reed RD, Shelton B, MacLennan PA, Kumar V, Mehta S, Mannon RB, Gaston R, Julian BA, Carr JJ, Terry JG, Kilgore M, Massie AB, Segev DL, Lewis CE.

Ann Surg. 2018 Jun;267(6):1161-1168. doi: 10.1097/SLA.0000000000002174.

20.

Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis.

Siwy J, Zürbig P, Argiles A, Beige J, Haubitz M, Jankowski J, Julian BA, Linde PG, Marx D, Mischak H, Mullen W, Novak J, Ortiz A, Persson F, Pontillo C, Rossing P, Rupprecht H, Schanstra JP, Vlahou A, Vanholder R.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2079-2089. doi: 10.1093/ndt/gfw337.

21.

Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index.

Julian BA, Gaston RS, Brown WM, Reeves-Daniel AM, Israni AK, Schladt DP, Pastan SO, Mohan S, Freedman BI, Divers J.

Am J Transplant. 2017 Jun;17(6):1540-1548. doi: 10.1111/ajt.14113. Epub 2017 Jan 3.

22.

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC.

J Am Soc Nephrol. 2017 Apr;28(4):1306-1313. doi: 10.1681/ASN.2016060640. Epub 2016 Nov 7.

23.

Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study.

Neprasova M, Maixnerova D, Novak J, Reily C, Julian BA, Boron J, Novotny P, Suchanek M, Tesar V, Kacer P.

Dis Markers. 2016;2016:3650909. Epub 2016 Oct 9.

24.

Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy.

Huang ZQ, Raska M, Stewart TJ, Reily C, King RG, Crossman DK, Crowley MR, Hargett A, Zhang Z, Suzuki H, Hall S, Wyatt RJ, Julian BA, Renfrow MB, Gharavi AG, Novak J.

J Am Soc Nephrol. 2016 Nov;27(11):3278-3284. Epub 2016 Mar 10.

25.

Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?

Suzuki H, Allegri L, Suzuki Y, Hall S, Moldoveanu Z, Wyatt RJ, Novak J, Julian BA.

Dis Markers. 2016;2016:7806438. doi: 10.1155/2016/7806438. Epub 2016 Aug 28.

26.

The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.

Knoppova B, Reily C, Maillard N, Rizk DV, Moldoveanu Z, Mestecky J, Raska M, Renfrow MB, Julian BA, Novak J.

Front Immunol. 2016 Apr 12;7:117. doi: 10.3389/fimmu.2016.00117. eCollection 2016. Review.

27.

Deceased-Donor Apolipoprotein L1 Renal-Risk Variants Have Minimal Effects on Liver Transplant Outcomes.

Dorr CR, Freedman BI, Hicks PJ, Brown WM, Russell GB, Julian BA, Pastan SO, Gautreaux MD, Muthusamy A, Chinnakotla S, Hauptfeld V, Bray RA, Kirk AD, Divers J, Israni AK.

PLoS One. 2016 Apr 7;11(4):e0152775. doi: 10.1371/journal.pone.0152775. eCollection 2016.

28.

New Insights into the Pathogenesis of IgA Nephropathy.

Novak J, Rizk D, Takahashi K, Zhang X, Bian Q, Ueda H, Ueda Y, Reily C, Lai LY, Hao C, Novak L, Huang ZQ, Renfrow MB, Suzuki H, Julian BA.

Kidney Dis (Basel). 2015 May;1(1):8-18. Epub 2015 May 1.

29.

APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors.

Freedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Bowden DW, Hicks PJ, Palmer ND, Palanisamy A, Reeves-Daniel AM, Brown WM, Divers J.

Transplantation. 2016 Jan;100(1):194-202. doi: 10.1097/TP.0000000000000969.

30.

Immune profile of IgA-dominant diffuse proliferative glomerulonephritis.

Wallace E, Maillard N, Ueda H, Hall S, Fatima H, Novak J, Julian BA.

Clin Kidney J. 2014 Oct;7(5):479-83. doi: 10.1093/ckj/sfu090.

31.

Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation.

Ma J, Divers J, Palmer ND, Julian BA, Israni AK, Schladt D, Pastan SO, Chattrabhuti K, Gautreaux MD, Hauptfeld V, Bray RA, Kirk AD, Brown WM, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Guan M, Palanisamy A, Reeves-Daniel AM, Bowden DW, Langefeld CD, Hicks PJ, Ma L, Freedman BI.

Kidney Int. 2015 Sep;88(3):584-92. doi: 10.1038/ki.2015.105. Epub 2015 Apr 8.

32.

Should kidney donors be genotyped for APOL1 risk alleles?

Freedman BI, Julian BA.

Kidney Int. 2015 Apr;87(4):671-3. doi: 10.1038/ki.2015.16. No abstract available.

33.

Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.

Freedman BI, Julian BA, Pastan SO, Israni AK, Schladt D, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Hicks PJ, Palmer ND, Adams PL, Palanisamy A, Reeves-Daniel AM, Divers J.

Am J Transplant. 2015 Jun;15(6):1615-22. doi: 10.1111/ajt.13223. Epub 2015 Mar 24.

34.

Current Understanding of the Role of Complement in IgA Nephropathy.

Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J.

J Am Soc Nephrol. 2015 Jul;26(7):1503-12. doi: 10.1681/ASN.2014101000. Epub 2015 Feb 18. Review.

35.

Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.

Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C, Viola BF, Dallera N, Del Vecchio L, Barlassina C, Salvi E, Bertinetto FE, Amoroso A, Savoldi S, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P, Magistroni R, Ghiggeri GM, Caridi G, Bodria M, Lugani F, Allegri L, Delsante M, Maiorana M, Magnano A, Frasca G, Boer E, Boscutti G, Ponticelli C, Mignani R, Marcantoni C, Di Landro D, Santoro D, Pani A, Polci R, Feriozzi S, Chicca S, Galliani M, Gigante M, Gesualdo L, Zamboli P, Battaglia GG, Garozzo M, Maixnerová D, Tesar V, Eitner F, Rauen T, Floege J, Kovacs T, Nagy J, Mucha K, Pączek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk K, Gale D, Barratt J, Thibaudin L, Berthoux F, Canaud G, Boland A, Metzger M, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N, Zhang H, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton RP, Gharavi AG.

Nat Genet. 2014 Nov;46(11):1187-96. doi: 10.1038/ng.3118. Epub 2014 Oct 12.

36.

N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy.

Stuchlova Horynova M, Vrablikova A, Stewart TJ, Takahashi K, Czernekova L, Yamada K, Suzuki H, Julian BA, Renfrow MB, Novak J, Raska M.

Nephrol Dial Transplant. 2015 Feb;30(2):234-8. doi: 10.1093/ndt/gfu308. Epub 2014 Oct 3.

37.

Cellular signaling and production of galactose-deficient IgA1 in IgA nephropathy, an autoimmune disease.

Reily C, Ueda H, Huang ZQ, Mestecky J, Julian BA, Willey CD, Novak J.

J Immunol Res. 2014;2014:197548. doi: 10.1155/2014/197548. Epub 2014 Jul 23. Review.

38.

Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy.

Takahashi K, Raska M, Stuchlova Horynova M, Hall SD, Poulsen K, Kilian M, Hiki Y, Yuzawa Y, Moldoveanu Z, Julian BA, Renfrow MB, Novak J.

PLoS One. 2014 Jun 11;9(2):e99026. doi: 10.1371/journal.pone.0099026. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e113577.

39.

A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.

Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, Makita Y, Julian BA, Novak J, Tomino Y.

PLoS One. 2014 May 23;9(5):e98081. doi: 10.1371/journal.pone.0098081. eCollection 2014.

40.

End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.

Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarcón GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, Niewold TB, Patel NM, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP; Lupus Nephritis–End‐Stage Renal Disease Consortium.

Arthritis Rheumatol. 2014 Feb;66(2):390-6. doi: 10.1002/art.38220.

41.

Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes.

Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian BA, Wyatt RJ, Tomino Y, Gharavi AG, Novak J.

J Biol Chem. 2014 Feb 21;289(8):5330-9. doi: 10.1074/jbc.M113.512277. Epub 2014 Jan 7.

42.

Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Hastings MC, Moldoveanu Z, Suzuki H, Berthoux F, Julian BA, Sanders JT, Renfrow MB, Novak J, Wyatt RJ.

Expert Opin Med Diagn. 2013 Nov;7(6):615-27. doi: 10.1517/17530059.2013.856878. Review.

43.

IgA nephropathy.

Wyatt RJ, Julian BA.

N Engl J Med. 2013 Jun 20;368(25):2402-14. doi: 10.1056/NEJMra1206793. Review. No abstract available.

PMID:
23782179
44.

Pathogenesis of immunoglobulin A nephropathy.

Novak J, Renfrow MB, Gharavi AG, Julian BA.

Curr Opin Nephrol Hypertens. 2013 May;22(3):287-94. doi: 10.1097/MNH.0b013e32835fef54. Review.

PMID:
23511518
45.

IgA nephropathy: molecular mechanisms of the disease.

Mestecky J, Raska M, Julian BA, Gharavi AG, Renfrow MB, Moldoveanu Z, Novak L, Matousovic K, Novak J.

Annu Rev Pathol. 2013 Jan 24;8:217-40. doi: 10.1146/annurev-pathol-011110-130216. Epub 2012 Oct 18. Review.

PMID:
23092188
46.

Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy.

Eison TM, Hastings MC, Moldoveanu Z, Sanders JT, Gaber L, Walker PD, Lau KK, Julian BA, Novak J, Wyatt RJ.

Clin Nephrol. 2012 Dec;78(6):465-9. doi: 10.5414/CN107423.

47.

The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy.

Tamouza H, Chemouny JM, Raskova Kafkova L, Berthelot L, Flamant M, Demion M, Mesnard L, Paubelle E, Walker F, Julian BA, Tissandié E, Tiwari MK, Camara NO, Vrtovsnik F, Benhamou M, Novak J, Monteiro RC, Moura IC.

Kidney Int. 2012 Dec;82(12):1284-96. doi: 10.1038/ki.2012.192. Epub 2012 Sep 5.

48.

Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.

Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J.

J Am Soc Nephrol. 2012 Sep;23(9):1579-87. doi: 10.1681/ASN.2012010053. Epub 2012 Aug 16.

49.

Serum galactose-deficient IgA1 level is not associated with proteinuria in children with IgA nephropathy.

Hastings MC, Afshan S, Sanders JT, Kane O, Eison TM, Lau KK, Moldoveanu Z, Julian BA, Novak J, Wyatt RJ.

Int J Nephrol. 2012;2012:315467. doi: 10.1155/2012/315467. Epub 2012 Jun 17.

50.

Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis.

Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG.

PLoS Genet. 2012;8(6):e1002765. doi: 10.1371/journal.pgen.1002765. Epub 2012 Jun 21.

Supplemental Content

Loading ...
Support Center